€24.50
0.49% day before yesterday
Amsterdam, Mar 07, 05:35 pm CET
ISIN
BE0003818359
Symbol
GLPG
Sector
Industry

Galapagos Stock price

€24.50
+2.42 10.96% 1M
-1.00 3.92% 6M
-2.02 7.62% YTD
-7.19 22.69% 1Y
-29.48 54.61% 3Y
-147.60 85.76% 5Y
+4.70 23.74% 10Y
Amsterdam, Closing price Fri, Mar 07 2025
-0.12 0.49%
ISIN
BE0003818359
Symbol
GLPG
Sector
Industry

Key metrics

Market capitalization €1.61b
Enterprise Value €-1.53b
P/E (TTM) P/E ratio 21.88
EV/FCF (TTM) EV/FCF 4.99
EV/Sales (TTM) EV/Sales -5.56
P/S ratio (TTM) P/S ratio 5.86
P/B ratio (TTM) P/B ratio 0.56
Revenue (TTM) Revenue €275.65m
EBIT (operating result TTM) EBIT €-229.11m
Free Cash Flow (TTM) Free Cash Flow €-307.25m
Cash position €3.16b
EPS (TTM) EPS €1.12
P/E forward negative
P/S forward 6.50
EV/Sales forward negative
Show more

Is Galapagos a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,808 stocks worldwide.

Galapagos Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Galapagos forecast:

1x Buy
8%
9x Hold
75%
2x Sell
17%

Analyst Opinions

12 Analysts have issued a Galapagos forecast:

Buy
8%
Hold
75%
Sell
17%

Financial data from Galapagos

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
276 276
-
100%
- Direct Costs 35 35
-
13%
241 241
-
87%
- Selling and Administrative Expenses 134 134
-
49%
- Research and Development Expense 335 335
-
122%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -229 -229
-
-83%
Net Profit 74 74
-
27%

In millions EUR.

Don't miss a Thing! We will send you all news about Galapagos directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galapagos Stock News

Neutral
GlobeNewsWire
13 days ago
Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that its management will present at the following investor conferences in March: TD Cowen 45 th Annual Healthcare Conference  Date: Tuesday, March 4, 2025Location: Boston,...
Positive
Seeking Alpha
17 days ago
Galapagos NV announced a strategic split with Gilead Sciences, creating 'New Galapagos' and 'SpinCo', aiming to unlock shareholder value and reduce staffing by 40%. 'New Galapagos' will focus on cell therapies and small molecules, while 'SpinCo' will target oncology, immunology, and virology with €2.45 billion in capital. Despite an 18% share decline post-announcement, the split offers deep val...
Neutral
GlobeNewsWire
20 days ago
Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital.
More Galapagos News

Company Profile

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Head office Belgium
CEO Paulus Stoffels
Founded 1999
Website www.glpg.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today